Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 88 citing articles:

Ebola
Heinz Feldmann, Armand Sprecher, Thomas W. Geisbert
New England Journal of Medicine (2020) Vol. 382, Iss. 19, pp. 1832-1842
Open Access | Times Cited: 169
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial
Andrew J. Pollard, Odile Launay, Jean‐Daniel Lelièvre, et al.
The Lancet Infectious Diseases (2020) Vol. 21, Iss. 4, pp. 493-506
Open Access | Times Cited: 144
Viral vector vaccines
Naina McCann, Daniel O’Connor, Teresa Lambe, et al.
Current Opinion in Immunology (2022) Vol. 77, pp. 102210-102210
Open Access | Times Cited: 71
Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines
Lynda Coughlan
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 118
Current state of Ebola virus vaccines: A snapshot
Courtney Woolsey, Thomas W. Geisbert
PLoS Pathogens (2021) Vol. 17, Iss. 12, pp. e1010078-e1010078
Open Access | Times Cited: 92
Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya
Gaudensia Mutua, Omu Anzala, Kerstin Lühn, et al.
The Journal of Infectious Diseases (2019) Vol. 220, Iss. 1, pp. 57-67
Open Access | Times Cited: 91
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
David Ishola, Daniela Manno, Muhammed O. Afolabi, et al.
The Lancet Infectious Diseases (2021) Vol. 22, Iss. 1, pp. 97-109
Open Access | Times Cited: 72
Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment
Jerome Custers, Denny Kim, Maarten Leyssen, et al.
Vaccine (2020) Vol. 39, Iss. 22, pp. 3081-3101
Open Access | Times Cited: 71
Designing of a Multi-epitope Vaccine against the Structural Proteins of Marburg Virus Exploiting the Immunoinformatics Approach
Saad Ahmed Sami, Kay Kay Shain Marma, Shafi Mahmud, et al.
ACS Omega (2021) Vol. 6, Iss. 47, pp. 32043-32071
Open Access | Times Cited: 70
Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP
Laura Solforosi, Harmjan Kuipers, Mandy Jongeneelen, et al.
The Journal of Experimental Medicine (2021) Vol. 218, Iss. 7
Open Access | Times Cited: 66
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial
Zacchaeus Anywaine, Houreratou Barry, Omu Anzala, et al.
PLoS Medicine (2022) Vol. 19, Iss. 1, pp. e1003865-e1003865
Open Access | Times Cited: 51
An introduction to the Marburg virus vaccine consortium, MARVAC
Robert W. Cross, Ira M. Longini, Stephan Becker, et al.
PLoS Pathogens (2022) Vol. 18, Iss. 10, pp. e1010805-e1010805
Open Access | Times Cited: 46
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial
Melinda Hamer, Katherine V. Houser, Amelia R. Hofstetter, et al.
The Lancet (2023) Vol. 401, Iss. 10373, pp. 294-302
Open Access | Times Cited: 37
Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate
Ramon Roozendaal, Jenny Hendriks, Thierry Van Effelterre, et al.
npj Vaccines (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 65
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa
Houreratou Barry, Gaudensia Mutua, Hannah Kibuuka, et al.
PLoS Medicine (2021) Vol. 18, Iss. 10, pp. e1003813-e1003813
Open Access | Times Cited: 54
The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform
Ariane Volkmann, Anna‐Lise Williamson, Heinz Weidenthaler, et al.
Vaccine (2020) Vol. 39, Iss. 22, pp. 3067-3080
Open Access | Times Cited: 52
Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases
Beatriz Perdiguero, Patricia Pérez, Laura Marcos-Villar, et al.
Journal of Molecular Biology (2023) Vol. 435, Iss. 15, pp. 168173-168173
Open Access | Times Cited: 20
Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates
John J. Suschak, Connie S. Schmaljohn
Human Vaccines & Immunotherapeutics (2019) Vol. 15, Iss. 10, pp. 2359-2377
Open Access | Times Cited: 43
Systematic review of Marburg virus vaccine nonhuman primate studies and human clinical trials
Nicholas Dulin, Adam J. Spanier, Kristen M. Merino, et al.
Vaccine (2020) Vol. 39, Iss. 2, pp. 202-208
Closed Access | Times Cited: 40
A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates
Ruth Hunegnaw, Anna N. Honko, Lingshu Wang, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 675
Closed Access | Times Cited: 27
First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study
Viki Bockstal, Georgi Shukarev, Chelsea McLean, et al.
PLoS ONE (2022) Vol. 17, Iss. 10, pp. e0274906-e0274906
Open Access | Times Cited: 25
Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases
Aurélie Wiedemann, Édouard Lhomme, Mélanie Huchon, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Methods to mitigate immune response
Chioma C. Ezeuko, Bernard B. Efa, Qiana L. Matthews
Elsevier eBooks (2025), pp. 275-308
Closed Access
Poxvirus-based vector systems and the potential for multi-valent and multi-pathogen vaccines
Natalie A. Prow, Rocio Jimenez Martinez, John D. Hayball, et al.
Expert Review of Vaccines (2018) Vol. 17, Iss. 10, pp. 925-934
Closed Access | Times Cited: 38
Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation
Chloé Pasin, Irène Balelli, Thierry Van Effelterre, et al.
Journal of Virology (2019) Vol. 93, Iss. 18
Open Access | Times Cited: 37
Page 1 - Next Page

Scroll to top